The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.
The consortium is helping create a new era of personalized medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.
FDA Guidance on the Qualification Process for Drug Development Tools was released in January 2014. For a link, click here >>:
The Bone Quality Project, managed by the Biomarkers Consortium Metabolic Disorders Steering Committee, aims to more precisely track the progression of osteoporosis and pave the way for more effective treatments.
LEARN HOW YOU CAN SUPPORT THE OSTEOPOROSIS RESEARCH>>
The Biomarkers Consortium Neuroscience Steering Committee is pleased to sponsor a CSF Proteomics Workshop More >>
Biomarkers Consortium of the Foundation for the NIH Constitutes Working Group to Assess Clinical Trial Design Issues for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia.
CLICK HERE FOR ADDITIONAL INFORMATION >>
Request for Letters of Intent on Biomarkers for Prediction of Response to Obesity Therapies and Sustained Weight Loss - The purpose of this RFI is to solicit preliminary ideas, resource estimates, and timelines regarding the creation and progressive validation of approaches to predict long-term weight loss response from short-term controlled weight loss clinical trials in adults.
CLICK HERE FOR THE RFI >>